1. Home
  2. HYFT vs EDSA Comparison

HYFT vs EDSA Comparison

Compare HYFT & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HYFT

MindWalk Holdings Corp.

HOLD

Current Price

$1.49

Market Cap

71.9M

Sector

Health Care

ML Signal

HOLD

Logo Edesa Biotech Inc.

EDSA

Edesa Biotech Inc.

HOLD

Current Price

$6.93

Market Cap

67.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HYFT
EDSA
Founded
1983
2015
Country
United States
Canada
Employees
102
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
71.9M
67.5M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
HYFT
EDSA
Price
$1.49
$6.93
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$5.00
$5.00
AVG Volume (30 Days)
256.4K
101.0K
Earning Date
03-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$29.18
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.99
$0.72
52 Week High
$3.00
$20.32

Technical Indicators

Market Signals
Indicator
HYFT
EDSA
Relative Strength Index (RSI) 46.22 45.58
Support Level $1.40 $4.87
Resistance Level $1.48 $9.00
Average True Range (ATR) 0.11 0.67
MACD -0.02 0.05
Stochastic Oscillator 32.30 14.38

Price Performance

Historical Comparison
HYFT
EDSA

About HYFT MindWalk Holdings Corp.

MindWalk Holdings Corp is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, MindWalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.

About EDSA Edesa Biotech Inc.

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.

Share on Social Networks: